Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development Actelion Pharmaceuticals Ltd Arena Pharmaceuticals Inc Astellas Pharma Inc AstraZeneca Plc Boston Pharmaceuticals Inc Bristol-Myers Squibb Co Celgene Corp GlaxoSmithKline Plc Idorsia Ltd LG Chem Ltd Novartis AG Sanofi Sun Pharma Advanced Research Company Ltd Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles AKP-11 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-0028 - Drug Profile Product Description Mechanism Of Action R&D Progress ASP-4058 - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-986104 - Drug Profile Product Description Mechanism Of Action R&D Progress BOS-173717 - Drug Profile Product Description Mechanism Of Action R&D Progress CBP-307 - Drug Profile Product Description Mechanism Of Action R&D Progress cenerimod - Drug Profile Product Description Mechanism Of Action R&D Progress CP-9531 - Drug Profile Product Description Mechanism Of Action R&D Progress etrasimod arginine - Drug Profile Product Description Mechanism Of Action R&D Progress FP-253 - Drug Profile Product Description Mechanism Of Action R&D Progress LC-510255 - Drug Profile Product Description Mechanism Of Action R&D Progress NIBR-0213 - Drug Profile Product Description Mechanism Of Action R&D Progress ozanimod hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress ponesimod - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-247799 - Drug Profile Product Description Mechanism Of Action R&D Progress SCD-044 - Drug Profile Product Description Mechanism Of Action R&D Progress siponimod - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones Featured News & Press Releases Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS Oct 19, 2017: Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting Oct 16, 2017: Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017 May 22, 2017: Celgene Announces Positive Results from RADIANCE, the Second Pivotal Phase III Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology Feb 21, 2017: TSRI-invented compound ozanimod shows positive results in late-stage clinical trial for relapsing multiple sclerosis Feb 17, 2017: Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis Feb 09, 2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 Oct 17, 2016: Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG Oct 13, 2016: Celgene to Present New Data on Ozanimod at UEGW and ACG Congresses Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Actelion Pharmaceuticals Ltd, H1 2018 Pipeline by Arena Pharmaceuticals Inc, H1 2018 Pipeline by Astellas Pharma Inc, H1 2018 Pipeline by AstraZeneca Plc, H1 2018 Pipeline by Boston Pharmaceuticals Inc, H1 2018 Pipeline by Bristol-Myers Squibb Co, H1 2018 Pipeline by Celgene Corp, H1 2018 Pipeline by GlaxoSmithKline Plc, H1 2018 Pipeline by Idorsia Ltd, H1 2018 Pipeline by LG Chem Ltd, H1 2018 Pipeline by Novartis AG, H1 2018 Pipeline by Sanofi, H1 2018 Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018

Actelion Pharmaceuticals Ltd Arena Pharmaceuticals Inc Astellas Pharma Inc AstraZeneca Plc Boston Pharmaceuticals Inc Bristol-Myers Squibb Co Celgene Corp GlaxoSmithKline Plc Idorsia Ltd LG Chem Ltd Novartis AG Sanofi Sun Pharma Advanced Research Company Ltd